ImClone Cancer Drug Does Not Increase Side Effects
Posted on: Friday, 19 January 2007, 12:01 CST
According to a new study, the addition of ImClone's Erbitux to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers.
This study was an in-depth look at outcomes from a study published in the New England Journal of Medicine in 2006. That study showed that patients with locally advanced head and neck cancer who were given Erbitux in addition to radiation therapy, showed not only a survival benefit, but also that there was no increase in mucositis or dysphagia over patients who received radiation therapy alone.
This study compared the duration of these normal tissue toxicities between the two arms from the England Journal of Medicine study. For the overall group, the median duration of any mucositis or dysphagia was three months. Of the patients with mucositis, 28% experienced this toxicity for three months. Of those with dysphagia, 31.5% experienced this toxicity for three months. Fewer than 10% suffered from these toxicities for more than 15 weeks. These findings were similar for the two treatment arms.
"These findings are important because they show that the addition of this monoclonal antibody therapy has lifesaving benefits without any additional length of suffering from the primary acute side effects," said James Bonner, radiation oncologist at the University of Alabama in Birmingham.
Merck KGaA, which holds the rights to Erbitux outside the US, has reported that its sales of the cancer treatment were up 55% in Q4, making the company $435.6 million.
Source: Datamonitor
Related Articles
- Some Radiation Therapy Treatments May Decrease Fertility
- Belgian Cancer Patients to Receive State-of-the-Art Radiation Therapy Treatments With New Technology From Elekta
- Acceletronics, Inc. Announces the Installation of 15 TheraView LX(R) Technology Electronic Portal Imaging Systems for Image Guided Radiation Therapy Treatment Verification
- Cancer Patients in New South Wales, Australia to Receive Advanced Image Guided Radiation Therapy Treatments With Arrival of New Elekta Linear Accelerators
- Tasmanian Cancer Patients to Receive Advanced Image-Guided Radiation Therapy Treatments With Arrival of New Varian Linear Accelerators With On-Board Imagers
- Machine Learning Could Speed Up Radiation Therapy for Cancer Patients
- AVAX Technologies Announces the Initiation of Its Clinical Study for the Treatment of Patients With Non Small Cell Lung Cancer
- ActivBiotics Announces Expansion of Phase-3 PROVIDENCE-1 Study of Antibiotic Treatment of Patients With Peripheral Arterial Disease During World's Largest Gathering of Cardiovascular Disease Researchers
- Radiation therapy can help spare vision in patients with melanoma of the eye
- First Study of Infliximab Treatment in Patients With Chronic Obstructive Pulmonary Disease
 |
 |
User Comments (0)
RSS Feeds